Cargando…
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
PURPOSE: Radical cystectomy (RC) is the standard treatment for high-risk non muscle-invasive bladder cancer (NMIBC) failing first BCG treatment. A second BCG course is an option for those patients who refuse RC or are not eligible for it, but its success rate is quite low. Aim of the present study w...
Autores principales: | Busetto, Gian Maria, Finati, Marco, Chirico, Marco, Cinelli, Francesco, D’Altilia, Nicola, Falagario, Ugo G., Sanguedolce, Francesca, Del Giudice, Francesco, De Berardinis, Ettore, Ferro, Matteo, Crocetto, Felice, Porreca, Angelo, Di Gianfrancesco, Luca, Calo’, Beppe, Mancini, Vito, Bettocchi, Carlo, Carrieri, Giuseppe, Cormio, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188396/ https://www.ncbi.nlm.nih.gov/pubmed/36971825 http://dx.doi.org/10.1007/s00345-023-04372-5 |
Ejemplares similares
-
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022) -
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
por: Racioppi, Marco, et al.
Publicado: (2018) -
Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA)
por: Kos, Bor, et al.
Publicado: (2016) -
Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
por: Barone, Biagio, et al.
Publicado: (2023) -
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study
por: Arrabal Polo, Miguel Ángel, et al.
Publicado: (2023)